MYOPATHY Clinical Trial
Official title:
High Dose Cyclophosphamide & ATG With Hematopoietic Stem Cell Transplantation in Patients With Refractory Idiopathic Inflammatory Myopathy Diseases: A Phase I Trial
Myositis is a disease, believed to be due to immune cells, cells which normally protect the body, but are now attacking the muscles and other organ systems within body. As a result, the affected muscles and organs fail to work properly causing weakness, difficulty swallowing, skin rash, respiratory problems, heart problems, joint stiffness, soft tissue calcification and vasculitis (blood circulation problems). The likelihood of progression of this disease is high. This study is designed to examine whether treating patients with high dose cyclophosphamide (a drug which reduces the function of the immune system) and ATG (a protein that kills the immune cells that are thought to be causing this disease), followed by return of previously collected blood stem cells will stop the progression of myositis.
Conditioning Regimen (In order to assure sterility testing, a minimum of 14 days will be
required between stem cell collection and starting the conditioning regimen).
The conditioning regimen is outlined in below:
Cyclophosphamide 50 mg/kg/day will be given IV over 1 hour in 250 cc of normal saline on day
-5, -4, -3, and -2. If actual weight is < ideal weight, cyclophosphamide will be given based
on actual weight. If actual weight is > ideal weight, cyclophosphamide will be given as
adjusted ideal weight. Adjusted ideal weight = ideal weight + 40% (actual weight minus ideal
weight).
Mesna 50mg/kg/day will be given IV over 24 hours in 250 cc of normal saline or D5W starting
at 10AM each dose. Weight base is calculated same as cyclophosphamide as above.
1ATG (rabbit) 0.5 mg/kg on day -6 and 1mg/kg on day -5, -4, -3, -2 and -1 (total 5.5mg/kg, no
dose adjustment) will be given IV over 10 hours in 250 cc of normal saline beginning at least
1 hour after infusion of cyclophosphamide. Premedicate with acetaminophen 650 mg po and
diphenhydramine 25 mg po/IV 30 minutes before the infusion.
Methylprednisolone- A suggested dose of 250mg IV should be administered 30 minutes before
each ATG infusion.
Hydration- A suggested rate of 125 cc/hr NS should be given starting 6 hours before the first
cyclophosphamide dose and continued until 24 hours after the last cyclophosphamide dose. The
rate of hydration will be aggressively adjusted. BID weights will be obtained. Amount of
fluid can be modified based on patient's fluid status. Minimum target urine output is 2
liters/m2/day
G-CSF 5 mcg/kg/day will be given subcutaneously and continued until the absolute neutrophil
counts reaches at least 500/µl.
Rituxan 500 mg will be given IV on the day before the first dose of ATG and the day after
stem cell infusion.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06374719 -
WiTNNess - TNNT1 Myopathy Natural History Study
|
||
Not yet recruiting |
NCT03633565 -
Comparative Study of Strategies for Management of Duchenne Myopathy (DM)
|
Phase 4 | |
Enrolling by invitation |
NCT02235220 -
Reduction of Masticatory Muscle Activity by Restoring Canine Guidance
|
N/A | |
Completed |
NCT01642056 -
EPI-743 for Metabolism or Mitochondrial Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02011282 -
Electro-Neuro-Muscular Stimulation in ICU
|
N/A | |
Completed |
NCT01702987 -
Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS
|
N/A | |
Active, not recruiting |
NCT01225614 -
Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive
|
Phase 3 | |
Recruiting |
NCT03749538 -
Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
|
N/A | |
Completed |
NCT02442986 -
Neurological Outcome in Surgical and Non-surgical Septic Patients
|
N/A | |
Recruiting |
NCT01022450 -
Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients
|
N/A | |
Withdrawn |
NCT00990834 -
Muscle Characteristics Associated With Statin Therapy
|
N/A | |
Active, not recruiting |
NCT00937001 -
Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness
|
N/A | |
Recruiting |
NCT01353430 -
Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
|
||
Completed |
NCT03751644 -
Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies
|
N/A | |
Completed |
NCT02765828 -
Identification of Tongue Involvement in Late-Onset Pompe Disease
|
||
Recruiting |
NCT05599568 -
Repeated Bout Effect i Neuromuscular Diseases
|
N/A | |
Withdrawn |
NCT02124070 -
Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis
|
Phase 1/Phase 2 | |
Completed |
NCT02706314 -
Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
|
||
Recruiting |
NCT03042286 -
SAPhIRE Statin Adverse Drug Reaction
|
||
Not yet recruiting |
NCT04941079 -
Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study
|